Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.50 |
| ▸ | WNT1 | P04628 | 6/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | SIK1 | P57059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706511 | 0.86 | PIK3C3 (0.53) | GSK3BDYRK1AWNT1PIK3C3 | |
| SCHEMBL19699545 | 0.86 | EP300 (0.46) | GSK3BDYRK1AWNT1EP300NR3C2 | |
| SCHEMBL19699553 | 0.84 | DYRK1A (0.57) | GSK3BDYRK1AWNT1EP300ABL1 | |
| SCHEMBL24932350 | 0.75 | EGFR (0.61) | GSK3BTYK2MAPTNPC1RAB9A | |
| SCHEMBL16105304 | 0.74 | MAPK14 (0.47) | NR3C2ABL1 | |
| SCHEMBL19699511 | 0.73 | WNT3A (0.47) | GSK3BDYRK1AWNT1TYK2MAPT | |
| SCHEMBL9891907 | 0.71 | RIOK2 (0.53) | GSK3BTYK2NR3C2MAPTNPC1 | |
| SCHEMBL29404187 | 0.71 | PIK3CD (0.52) | DYRK1AMAPK1 | |
| SCHEMBL19699532 | 0.71 | GSK3B (0.57) | GSK3BDYRK1AWNT1 | |
| SCHEMBL28668448 | 0.71 | NAMPT (0.49) | DYRK1AMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GSK3B 2322/4885DYRK1A 3048/4885WNT1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.